News Digest 24.07.2024 — 26.07.2024
Regulators
Tatyana Golikova presented the content of new federal projects. Main
At the beginning of her speech, Tatyana Golikova recalled that the overall goal by 2030 is to achieve a life expectancy (LE) of 78 years, and presented current data on the indicator by region. She asked to pay special attention to the regions of the Far East, Central and Northwestern Federal Districts, where the LE level is either below 70 years or below the average for the Russian Federation - 73.4 years.
According to surveys by the Government of the Russian Federation, it is the national project "Healthcare", the successor of which will be the new project, that Russian residents consider the most promising of the rest, the Deputy Prime Minister noted. In general, the healthcare system affects LE indicators by 38%, according to the Cabinet's analysis.
National project "Long and active life"
For the first time, Golikova's slides publicly presented specific activities of the new national project, for which federal and regional funds will be allocated (their amount has not yet been determined).
The main activities of the project:
- Purchase of vehicles for the regions (except ambulances). The number of vehicles should increase from 2.4 thousand in 2023 to 9,574 in 2030.
- Creation of healthcare facilities - an increase from 1.1 thousand to 4.4 thousand units.
- Major repairs of buildings in cities with a population of up to 100 thousand people - from 1.3 thousand to 8.4 thousand units.
- Purchase of equipment for cities of the same type - from 39 thousand to 86.4 thousand units.
It is also planned to open primary vascular departments and outpatient oncology care centers (AOCC) in small cities and towns, increase the number of visits of mobile medical teams and the audience of the project on remote monitoring of health status.
Market news
Production of medicines and medical devices in Moscow increased by 12.7% in five months of 2024
In the first five months of 2024, the production volume of medicines and medical devices increased by 12.7% compared to the same period last year, the press service of the Moscow government reported, citing Deputy Mayor of Moscow for Transport Maxim Liksutov.
According to him, the production of pharmaceutical substances increased more than 2.8 times, and the volume of shipped products rose by almost 10% and exceeded 116 billion rubles. In physical terms, the production volume of diagnostic reagents and other pharmaceuticals increased by 17.6%, and the volume of adhesive dressings, catgut and similar materials, first aid kits and sanitary bags - more than 1.5 times.
According to the head of the Moscow Department of Investment and Industrial Policy Anatoly Garbuzov, in physical terms, the volume of drug production increased by 20.9% over five months. The production of drugs for the treatment of diseases of the digestive tract and metabolism increased by 35.5% and amounted to more than 420 thousand packages. During this period, more than 483 thousand drugs in ampoules affecting hematopoiesis and blood were produced, which is almost 42% more than the same period last year. The growth in the production of drugs for the treatment of the nervous system was 12.9% - more than 11 million packages.
In Moscow, 22 offset contracts have already been concluded, three of which are for the production of medical products. Under some agreements, production facilities have already been built or modernized and products are being delivered.
"Offset contracts help the capital provide city medical organizations with medicines and medical products necessary to provide effective assistance. For example, these are products for ostomy patients: in 2023 alone, we received over 3.8 million units of products for a total of over 1.1 billion rubles," shared Deputy Mayor for Social Development Anastasia Rakova.
The Ministry of Industry and Trade announced the launch of Russian continuous glucose monitoring systems on the market
Three Russian manufacturers are currently developing continuous glucose monitoring (CGM) systems: Elta, Medtechservice and PalMed. They will launch their products on the market in 2024–2026. This was announced by Deputy Minister of Industry and Trade Ekaterina Priezzheva at the plenary session of the Healthy Society forum, a correspondent for FV reports.
According to Priezzheva, ELTA Company LLC will register in 2025, and will launch serial production of 500 thousand units starting in 2026. NMG systems per year, Medtechservice LLC will register and launch serial production of 300 thousand NMG systems per year this year, and PalMed (Palmed LLC) will register and launch serial production of 750 such systems per year in the first quarter of 2025 from the third quarter.
“All these companies have the production capacity to increase if necessary,” the deputy minister emphasized.
Deputy Prime Minister Tatyana Golikova added that the government, together with the Russian dravnadzor and the Federal State Budgetary Institution "National Medical Research Center of Endocrinology" of the Ministry of Health monitor the situation with the NMG systems in the country.
"We see feedback from citizens, but it does not always correspond to reality. We <...> closely monitor this," she said.
According to the Deputy Prime Minister, within the framework of another project, which is related to the technologies of medicine of the future, there is a federal project related to the support of domestic production of drugs and medical devices. The project is needed to ensure the independence of the Russian market from the actions of unfriendly countries and from the possible withdrawal of foreign drugs.
Golikova warned NMIC against "fragmented" purchase of medical equipment
Federal medical organizations (FMO) will have to submit to the government development programs that will comprehensively address the issue of introducing advanced diagnostic and treatment methods for complex patients by the fall of this year. This was announced on July 24 by Deputy Prime Minister Tatyana Golikova at the Healthy Society 2024 forum, the MV correspondent reports.
Talking about the new national project "Long and Active Life", which provides for the modernization of FMO and the expansion of the network of national research medical centers (NMIC), Golikova recalled that since 2021 they have been financed directly from the budget of the Federal Compulsory Medical Insurance Fund. Over the past three years, the FMOs have accumulated certain experience and changed the structure of hospitalized patients, and began to provide assistance, as expected, to patients with complex and severe diseases from all regions of the country. Now it is necessary to ensure further development of these institutions so that they actively implement advanced medical technologies for the diagnosis and treatment of diseases and then spread their experience to other regional medical organizations.
Investtorg to sell debt claims against the manufacturer of medical glass Altair
The Russian Auction House (RAD) will hold an auction to sell the claims of Investtorg LLC against Altair LLC. The starting price of the right to request repayment of accounts payable will be 2.49 billion rubles. The main collateral asset for the loan is the Klin-Pharmaglas production site with an area of 14 hectares in the Moscow Region. The auction will take place on August 15, 2024.
As specified by the RAD, the bidding will be held with a decrease in price. The minimum price is set at 1.05 billion rubles.
Investtorg's claims against Altair arose on the basis of six loan agreements. The Klin-Pharmglass site is engaged in the production of medical glass - ampoules and vials for packaging drugs. The complex includes a land plot of 14 hectares, a building, 15 production lines of a plant for the manufacture of specialized products. The RAD emphasized that the claims against the Altair company and the guarantor for Klin-Pharmglass loans are guaranteed to be fulfilled in full.
According to SPARK-Interfax, Klin-Pharmglass LLC was registered in Klin, Moscow Region, in 2000. The beneficiary of the legal entity is Altair LLC. In 2023, revenue amounted to 649.9 million rubles with a loss of 283.3 million rubles. Since February 2024, the legal entity has been under supervision in the bankruptcy case. Altair LLC was registered in St. Petersburg in 1997. Altair - St. Petersburg LLC owns 99.9% of the shares of the subsidiary, Veronika Balaneva - 0.002%. SPARK-Interfax does not have financial data for the company for 2023, and in 2022 it earned 11.6 billion rubles with a net profit of 276 million rubles. In April 2024, bankruptcy proceedings were opened against the legal entity for six months. The decision to declare the legal entity bankrupt was made by the Arbitration Court of St. Petersburg and the Leningrad Region, which also appointed Lyudmila Samsonova as the bankruptcy trustee of the asset. The list of Altair's creditors includes Investtorg, Grotex (manufactures products under the Solopharm brand), Sberbank and others. The Business News Agency also reported that at the end of 2023, Altair was included in the register of unscrupulous suppliers.
In June 2024, Favorit Trade acquired the Sfera-Pharm pharmaceutical complex for 1.4 billion rubles. The property was put up for auction in December 2023, after the plant's legal entity was declared bankrupt. The initial price of the enterprise was 2.1 billion rubles.
BSS invested 1 billion rubles in the production of endoprostheses
The EndoArt company (part of the BSS holding) in St. Petersburg is preparing to open a production facility for hip joint endoprostheses. The launch will take place in August.
The capacity is 35 thousand cemented and cementless fixation products per year.
The products will have to compete not so much with giants like Zimmer, Smith & Nephew and Stryker, with whom, according to DT, there are already difficulties in public procurement, how much with Chinese manufacturers - Double Medical, for example. Since 2022, they are increasingly included in the clinical practice of traumatologists-orthopedists.
Source: https://t.me/delotom/460
GE Healthcare brought SPECT/CT to the Russian market
Just in time for the announcement of purchases of equipment for radionuclide diagnostics, under the national project until 2030, GE Healthcare LLC received a registration certificate for a new SPECT/CT.
The StarGuide system is a relatively new SPECT/CT model, it was presented in Europe only in 2021. The radiopharmaceutical lutetium-177 is used for visualization, it is intended for diagnostics and assessment of the patient's response to treatment of neuroendocrine cancer and prostate cancer.
The device is positioned as focused on theranostics. Given how few medical organizations are working in this area, it is very interesting who could acquire the new product. On the fingers of one hand - a couple of NMIC, JSC "Medicine", MIBS, there were such ambitions in the "Beloostrov" clinic.
In Canada, for example, such a device was installed for the first time this year and its cost is estimated at $ 1.5 million.
Source: https://t.me/delotom/461
Other
Bangkok Hospital introduces patient registration system based on artificial intelligence
Bangkok Hospital, in partnership with Agnost Health, has developed a patient registration system using artificial intelligence (AI) technology.
After two years of development, a fully operational intelligent registration system is available via self-service kiosks or tablets for staff for services such as patient identity verification and initial symptom screening.
" We invest in what benefits patients . “The goal of developing this system is to streamline processes for our customers and set service standards,” said Somrit Jantharapratin, Deputy Chief Information Officer at Bangkok Hospital Group.
To achieve this goal, the new system aims to reduce registration steps by 45% and digitize patient information to minimize data entry errors.
“Another obvious benefit is the elimination of paper documentation. Digital transformation must align with environmental, social and governance (ESG) principles, such as reducing paper use,” Jantharapratin added.
Newly registered medical products
We publish a list of new medical products registered from 19.07.2024 to 26.07.2024
Link to the list: [see table in the attachment]
News
